[Anónimo]

For patients with evidence of low volume residual disease following completion of initial chemotherapy, I favor a maintenance strategy with an aromatase inhibitor such as letrozole; this is based upon an extrapolation of the activity of hormonal therapies in recurrent disease, not on prospective data post cycle therapy nolvadex There was a lot of trauma